- Home
- Most Recent Content
Most Recent Content
Multidisciplinary Approaches to Improve Pulmonary Embolism (PE) Management - Latest Clinical Data
- 1.00
Published:
Learning objectives
- Enhance clinician understanding of current PE management
- Promote the Multidisciplinary Team (MDT) approach in PE management
- Familiarise clinicians with the latest data from the PEERLESS study
Decoding the Future of Heart Failure — Emerging Strategies in HF with EF ≥40%: Key Takeaways from 2024
- 1.00
Published:
Learning objectives
- Summarise the long-term burden and current unmet needs for patients with HF and EF ≥40%
- Recall data on new therapies being evaluated in the HFmr/pEF population, including data from the AHA 2024 annual congress
- Describe how non-steroidal MRAs differ in their mechanism of action and elicit their benefits in HF
Medical Options for Advanced HFpEF/HFmrEF Patients: An Expert-Guided Virtual Ward Round
- 1.00
Published:
Learning objectives
- Describe the current limitations of HFmrEF/HFpEF GDMT in advanced patients
- Select appropriate patients for advanced medical therapy
- Recall recent trial data for novel therapeutic approaches
- Use expert guidance to develop an evidence-based approach to managing advanced HFmrEF/HFpEF
Advancements in Triglyceride-lowering Therapies
- 1.00
Published:
Learning objectives
- Recall the primary and secondary outcomes from key triglyceride-lowering trials presented during ESC 2024
- Discuss the current and future implication of trial results to clinical management and practice guidelines
Bridging the Gap in Worsening Heart Failure: Evidence-Based Approaches to Optimising Treatment Outcomes
- 1.25
Published:
Learning objectives
- To identify high-risk patient features indicative of worsening Heart Failure (HF)
- Name validated tools for serial prognostic assessment and risk stratification
- Adopt the use of appropriate assessment tools during patient follow-up
- Recall rates of recurrent HF events and their associated healthcare costs in worsening HF patients
- Recall the clinical benefit of emerging treatments targeted to treating worsening HF
- Initiate available treatment for the tailored management of worsening HF
The Bigger Picture: An Expert Assessment on the True Impact of ATTR-CM
- 1.00
Published:
Learning objectives
- Recall the most recent epidemiological data on ATTR-CM incidence and diagnostic trends
- List red flags indicating the presence of ATTR amyloidosis
- Identify patients who should undergo detailed diagnosis work-up or referral
- List the advantages of emerging classes of agents being evaluated in ATTR-CM
AF Stroke Prevention – Applying New Guidance in the Real World
- 1.00
Published:
Learning objectives
- Recall the risk of ischaemic stroke in AF patients
- Compare therapeutic efficacy and risk between left atrial appendage closure and oral anticoagulation in atrial fibrillation
- Review European guideline updates on the use of left atrial appendage closure in atrial fibrillation
- Summarise the clinical evidence behind non-pharmacological approaches to stroke prevention in atrial fibrillation
Cardiac Amyloidosis: Emerging Diagnostic and Treatment Approaches
- 1.00
Published:
Learning objectives
- Understand the nature of amyloidosis and its effects on various organs, particularly the heart
- Distinguish between light-chain (AL) amyloidosis, wild type TTR amyloidosis and hereditary TTR amyloidosis in terms of their clinical manifestations and their different treatments
- Recognise the novel challenges of managing heart failure in cardiac amyloidosis, including both medical management and the role of devices
- Understand the critically important interaction between haematologists and cardiologists in the therapy of AL amyloidosis
- Develop an understanding of novel therapies currently in clinical trials of TTR and AL amyloidosis
- Identify their own roles and responsibilities in the management TTR and AL amyloidosis as part of a multidisciplinary team
Advancing Patient Care in Hypertrophic Cardiomyopathy
- 0.50
Published:
Learning objectives
- Recall recent trial data for novel disease modifying therapy in HCM
- Describe the evolving guideline directed approach to managing HCM
- Develop an expert-led approach to implementing novel therapy in clinical practice